<DOC>
<DOCNO>EP-0633881</DOCNO> 
<TEXT>
<INVENTION-TITLE>
AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3113	A61K3147	A61K314402	A61K31195	A61K3127	C07D21512	A61K314427	A61P3112	C07C32360	A61K3124	A61K314418	C07C27120	C07C32300	C07D23154	A61K3150	A61P3700	A61K3150	A61K3144	A61P3704	A61P3100	A61P3118	A61K314402	A61K3121	A61K3147	C07D21324	A61K3113	C07C32323	C07C24300	C07C24326	A61K314418	C07D23726	C07C24312	A61K3144	C07C24328	C07D23730	C07C27100	C07D23100	C07D23704	A61K31185	A61K314427	C07D40100	C07D40112	C07D21300	C07D21500	C07D21330	C07D23700	C07D21381	C07D21548	C07C28100	A61K3115	A61K3115	C07C28102	C07D23708	C07C24314	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	C07D	A61K	A61P	C07C	A61K	A61K	C07C	C07C	C07D	A61K	A61P	A61K	A61K	A61P	A61P	A61P	A61K	A61K	A61K	C07D	A61K	C07C	C07C	C07C	A61K	C07D	C07C	A61K	C07C	C07D	C07C	C07D	C07D	A61K	A61K	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07C	A61K	A61K	C07C	C07D	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	C07D215	A61K31	A61P31	C07C323	A61K31	A61K31	C07C271	C07C323	C07D231	A61K31	A61P37	A61K31	A61K31	A61P37	A61P31	A61P31	A61K31	A61K31	A61K31	C07D213	A61K31	C07C323	C07C243	C07C243	A61K31	C07D237	C07C243	A61K31	C07C243	C07D237	C07C271	C07D231	C07D237	A61K31	A61K31	C07D401	C07D401	C07D213	C07D215	C07D213	C07D237	C07D213	C07D215	C07C281	A61K31	A61K31	C07C281	C07D237	C07C243	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The compounds of general formula (1) wherein R
<
1
>
, R
<
2
>
, R
<
3
>
 are optionally substituted carbonyl and amide derivatives which are useful as inhibitors of retroviral proteases, and are effective in treating conditions characterized by unwanted activity of these enzymes, such as acquired immune deficiency syndrome.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The invention relates to certain amine derivatives and their use in the inhibition
of human immunodeficiency virus (HIV) proteases and thus in the treatment of HIV
viral infections such as acquired immunodeficiency syndrome (AIDS).Human immunodeficiency virus (HIV) is a pathogenic retrovirus causing
AIDS and its related disorders. The development of antiviral chemotherapy against
AIDS has been the subject of an intense research effort since the discovery of HIV.
(For a recent review on molecular targets for AIDS therapy see Mitsua et al, Science,
1990, pp 1533-1544). The HIV Proteases (HIV PR), and aspartyl proteases, were first
suggested as a potential target for AIDS therapy by Kramer et al. (Science, 231, 1580,
1986). Since that time the potential usefulness of HIV PR inhibitors as effective agents
in treatment of AIDS has been widely recognized (for a review of the HIV PR as a
therapeutic target see Tomaselli et al. Chimica Oggi, May 1991, pp 6-27 and Huff J.R.,
J.Med.Chem., 1991, 34, 2314-2327). Of the classical transition state mimics for
aspartyl proteases, the hydroxyethylene, dihydroxyethylene, hydroxyethyl amine and
phosphinic acid isosteres appear to provide the greatest affinity for HIV PR. Many
inhibitors of HIV PR have been shown to have an antiviral activity at concentrations in
the nanomolar range in the different cell systems and are described as such in the patent
literature.Huff J.R., J.Med. Chem. (1991) 34, 2314-2327 describes certain protease
inhibitors based on dipeptide isostere replacements for the scissile bond in aspartyl
protease substrates.Other documents which disclose HIV protease inhibitors include Australian
Patent Application No. 63221/90, Australian Patent Application No. 55711/90 and
European Patent Application No. 521827. Australian Patent Application No. 63221/90
discloses a number of 1,6-disubstituted hexane-3,4-diol derivatives, and Australian 
Patent Application No. 55711/90 discloses a range of substituted amino acid derivatives
having retroviral protease inhibiting activity. European Patent Application No. 521827
also discloses compounds having an antiviral activity.United States Patent No. 3330857 discloses certain hydrazide derivatives
which may be regarded as derivatives of an amino acid in which the Î±-methylidyne
group is replaced by a nitrogen atom. However, US 3330857 does not disclose
compounds having HIV protease inhibiting activity.The invention provides a new class of compounds which are useful as
inhibitors of retroviral proteases, particularly
</DESCRIPTION>
<CLAIMS>
A compound selected from the group consisting of:

t-Butyl 3-isopropyl-[(2R,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2R,3S)-2-hydroxy-3-(N-quinaldyl-L-valyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2R, 3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)-amino-4-phenylbutyl]carbazate
1-(2-pyridyl)methoxycarbonylanthranilyl-2-[(2R,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]-2-isopropyl-hydrazine
t-Butyl 3-isopropyl-3-[(2-oxo-3(S)-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-(1-methyl-3-phenylpropen-3-yl)-3-[(2R and S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-(1-methyl-3-phenylpropyl)-3-[(2R,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo-[4.4.0]
decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(N-quinaldyl-L-valyl)-amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-[N-(2-pyridyl)-methoxycarbonyl-L-valyl]amino-4-phenylbutyl]
-3,4-diaza-bicyclo[4.4.0]decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(N-quinaldyl-L-glutaminyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane 
cis-1,6-3-t-Butoxycarbonyl-4-[(2RS,3S)-2-hydroxy-3-(N-quinaldyl-L-threonyl)-amino-4-phenylbutyl[-3,4-diaza-bicyclo[4.4.0]decane
2-t-Butoxycarbonyl-3-[(2RS,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1]
hept-5-ene
2-t-Butoxycarbonyl-3-[(2RS,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2,3-diaza-bicyclo[2.2.1]
heptane
2-t-Butoxycarbonyl-3-[(2RS, 3S)-2-hydroxy-3-[N-(2-pyridyl)-methoxycarbonyl-L-valyl]amino-4-phenylbutyl]
-2,3-diaza-bicyclo[2.2.1]-heptane
2-[N-(1S)(2-methyl-1-methoxycarbonylpropyl)carbamoyl]-3-[(2RS,3S)-2-hydroxy-3-[N-(2-pyridyl)methoxy-L-valyl]
amino-4-phenylbutyl]-2,3-diazabicyclo[2.2.1]
heptane
2-t-Butoxycarbonyl-3-[(2RS, 3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)-amino-4-phenylbutyl]-1,2,3,4-tetrahydrophthalazine
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)-amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
cis-1,6-3-t-Butoxycarbonyl-4-[2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)-amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2S, 3S)-2-hydroxy-3-amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane
cis-1,6-3-t-Butoxycarbonyl-4-[(2S, 3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane
1-Trimethylacetyl-2-[(2S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]-2-isopropylhydrazine
1-Trimethylacetyl-2-[(2S,3 S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]-2-isopropylhydrazine
1-(t-Butylamino)carbonyl-2-[(2S,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)-amino-4-phenylbutyl]-2-isopropylhydrazin
e
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(N-picolinoyl-L-asparaginyl)amino-4-phenylbutyl]carbazate 
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(N-(2-pyridyl)methoxycarbonyl-anthranilyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-benzyl-3-[(2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-benzyl-3-[(2S,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-cyclohexyl-3-[(2S, 3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-cyclohexyl-3-[(2S, 3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2S,3S)-2-hydroxy-3-(N-(1-carbamoylmethyl)acrylyl)-amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(N-2-(RS)-3-tert-butylthio-2-carbamoylmethylpropionyl)amino-4-phenylbutyl]carbazate
t-Butyl 3-isopropyl-3-[(2S, 3S)-2-hydroxy-3-(N-benzoyl-L-asparaginyl)amino-4-phenylbutyl]carbazate
1-t-Butyloxycarbonyl-2-[(2S,3S)-2-hydroxy-3-(phenylmethoxycarbonyl)amino-4-phenylbutyl]hexahydropyridazine
1-t-Butyloxycarbonyl-2-[(2S,3S)-2-hydroxy-3-(N-quinaldyl-L-asparaginyl)-amino-4-phenylbutyl]hexahydropyridazine
cis-1.6-3-t-Butoxycarbonyl-4-[(2S,3S)-2-hydroxy-3-(N-quinaldyl-3-cyano-L-alanyl)amino-4-phenylbutyl]-3,4-diaza-bicyclo[4.4.0]
decane.
A pharmaceutical composition comprising a compound according to Claim 1
together with one or more pharmaceutically acceptable carriers.
Use of a compound according to Claim 1 for the manufacture of a medicament
for inhibiting a retroviral protease in a mammal in need of such retroviral protease

inhibition.
Use according to Claim 3 wherein the retroviral protease is an HIV protease. 
Use of a compound according to Claim 1 for the manufacture of a medicament
for the treatment or prophylaxis of acquired immune deficiency syndrome in a mammal

in need of such treatment.
</CLAIMS>
</TEXT>
</DOC>
